Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Relatlimab + Chemotherapy vs Pembrolizumab + Chemotherapy in 1L NSQ NSCLC
NCT06561386Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2024
- Primary completion
- Jul 2030
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 31
01
Overview
A Phase 3 trial of nivolumab, relatlimab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Oct 2024; status: recruiting.
02
Drugs
nivolumabrelatlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06561386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06561386.